Trial Profile
Real life data on Olaparib in BRCA1/2 mutated Epithelial Ovarian Cancer patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jan 2016
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- 21 Jan 2016 New trial record